Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital (2016 - 2025)

Historic Invested Capital for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $523.9 million.

  • Viridian Therapeutics, Inc.\DE's Invested Capital fell 2804.31% to $523.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $523.9 million, marking a year-over-year decrease of 2804.31%. This contributed to the annual value of $692.2 million for FY2024, which is 4975.78% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Invested Capital stood at $523.9 million for Q3 2025, which was down 2804.31% from $536.0 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Invested Capital high stood at $728.0 million for Q3 2024, and its period low was $98.9 million during Q2 2021.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Invested Capital had a median value of $399.7 million in 2022 and averaged $390.7 million.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 87229.83% in 2021, then crashed by 2804.31% in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Invested Capital (Quarter) stood at $187.7 million in 2021, then soared by 112.93% to $399.7 million in 2022, then grew by 15.64% to $462.2 million in 2023, then surged by 49.76% to $692.2 million in 2024, then decreased by 24.32% to $523.9 million in 2025.
  • Its Invested Capital was $523.9 million in Q3 2025, compared to $536.0 million in Q2 2025 and $625.2 million in Q1 2025.